Results demonstrate Esopredict’s ability to predict the likelihood of progression to high-grade dysplasia or esophageal adenocarcinoma in patients with Barrett’s esophagus. BALTIMORE, Aug. 15, 2024 /PRNewswire/ — Previse, a gastrointestinal health company, announced today that its…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.